SAN FRANCISCO, Oct. 23 /PRNewswire-FirstCall/ -- Genomic Health today announced that the Company will hold a business and scientific briefing on Thursday, November 12, 2009 beginning at 12:30 p.m. ET in New York City.
Members of Genomic Health’s management team will discuss how the company is breaking barriers in new areas of molecular diagnostics and genomic analysis. Speakers will focus on Genomic Health’s business model, research and development, technology platform and patient centric philosophy as driving factors for making individualized cancer treatment the standard of care. In addition, the meeting will feature a presentation by Norman Wolmark, M.D., chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP), and the Department of Human Oncology at Allegheny General Hospital in Pittsburgh, Pennsylvania, centered on the need for individualized cancer treatment and his experience in both breast and colon cancer.
To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health’s website at http://investor.genomichealth.com. Please connect to the website at least 15 minutes prior to the beginning of the presentation to allow for any necessary software downloads. An archived replay will be available beginning 24 hours after the live presentation.
About Genomic Health
Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health is preparing to launch its Oncotype DX colon cancer test in early 2010. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s plans to commercialize a test for colon cancer and the proposed timing of such commercialization. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of our tests; the risks and potential delays associated with commercialization of a new test; and the other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype and Oncotype DX are trademarks or registered trademarks of Genomic Health, Inc.
SOURCE Genomic Health, Inc.
CONTACT: Emily Faucette of Genomic Health, +1-650-569-2824,
media@genomichealth.com
Web site: http://www.genomichealth.com/
